Immunotherapy With Baricitinib and Sirolimus, Alone and in Combination, for the Control of HIV-1 Replication After Antiretroviral Treatment Interruption

NCT07081763 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

191

Enrollment

OTHER_GOV

Sponsor class

Conditions

HIV-1-infection

Interventions

DRUG: Baricitinib 2 MG
DRUG: Sirolimus 2 MG
OTHER: Placebo of baricitinib 2 MG
OTHER: Placebo of sirolimus 2 MG

Sponsor

ANRS, Emerging Infectious Diseases